Lone Star Bio

Found 17,183 articles

• Waters Boosts Resolution and Triples Scan Speed of SELECT SERIES MRT for Metabolomics and MS Imaging

  6/5/2023

  Waters Corporation announced new updates to its SELECT SERIES™ MRT System that increases its specificity and utility for UPLC-MS/MS metabolomics and drug discovery applications and for mass spectrometry imaging experiments.

• Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer’s Disease (AD)

  6/5/2023

  Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the appointment of Dr. Guillaume Dorothée, Ph.D., to Coya’s SAB, joining a roster of scientific luminaries.

• Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational Dermatology

  6/5/2023

  Castle Biosciences, Inc. today announced the publication of a paper in Clinical, Cosmetic and Investigational Dermatology highlighting a clinician-derived, real-world algorithm that provides a framework to incorporate DecisionDx®-SCC test results into clinical practice within National Comprehensive Cancer Network (NCCN) guideline recommendations.

• Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares

  6/5/2023

  Lexicon Pharmaceuticals, Inc. announced the closing of Lexicon’s previously announced public offering and concurrent private placement of shares of its common stock.

• Waters Takes Targeted, Quantitative Imaging to the Next Level with New DESI Source for the Xevo TQ Absolute System

  6/5/2023

  Waters Corporation launched the industry's first targeted imaging mass spectrometer based on its Xevo™ TQ Absolute tandem quadrupole mass spectrometer, the most sensitive and compact mass spectrometer in its class.

• GALDERMA RECEIVES FDA APPROVAL FOR ITS NEWEST HYALURONIC ACID FILLER, RESTYLANE® EYELIGHT

  6/5/2023

  Galderma announced today the U.S. Food and Drug Administration (FDA) approved Restylane® Eyelight for the treatment of undereye hollows, also known as dark shadows, in adults over the age of 21.

• PreOmics Introduces New ENRICH-iST Kits and Novel Workflow for Unbiased, Affordable Plasma and Serum Proteomics by LC-MS

  6/5/2023

  PreOmics Introduces New ENRICH-iST Kits and Novel Workflow for Unbiased, Affordable Plasma and Serum Proteomics by LC-MS.

• Bruker Introduces Novel EVOQ™ DART-TQ+ for Chromatography-Free Mass Spectrometry Aimed at the Applied Market Segments

  6/5/2023

  Bruker Introduces Novel EVOQ™ DART-TQ + for Chromatography-Free Mass Spectrometry Aimed at the Applied Market Segments.

• Bruker Launches timsTOF Ultra Mass Spectrometer with Transformative Sensitivity, 300 Hz PASEF MS/MS, and VistaScan™ for Enhanced dia-PASEF® 4D-Proteomics™

  6/5/2023

  Bruker Launches timsTOF Ultra Mass Spectrometer with Transformative Sensitivity, 300 Hz PASEF MS/MS, and VistaScan™ for Enhanced dia-PASEF® 4D-Proteomics™.

• Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection

  6/5/2023

  Natera, Inc., a global leader in cell-free DNA testing, announced new data on its Prospera test being presented at the American Transplant Congress 2023 taking place June 3-7, 2023.

• Nanoscope Therapeutics to Present at the BIO International Convention

  6/5/2023

  Nanoscope Therapeutics Inc. today announced that management will present at the BIO International Convention, taking place June 5-8, 2023, in Boston, MA.

• Thermo Fisher Scientific Showcases Solutions for Accelerating Biological Discovery

  6/5/2023

  Thermo Fisher Scientific is showcasing new mass spectrometry and chromatography instruments, software and workflows that enable customers to unlock deeper analytical insights, improve productivity and accelerate biological discovery.

• Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting

  6/3/2023

  Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that new data on DecisionDx®-Melanoma and DecisionDx®-UM will be shared during the 2023 American Society of Clinical Oncology Annual Meeting, taking place June 2-6.

• Savara to Present at the 2023 Jefferies Healthcare Conference

  6/2/2023

  Savara Inc. announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT.

• RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial

  6/1/2023

  RenovoRx, Inc today announced that the University of Texas (UT) Southwestern Medical Center is now enrolling pancreatic cancer patients in the open label, randomized Phase III TIGeR-PaC clinical trial.

• Plus Therapeutics Provides Company Update Today

  6/1/2023

  Plus Therapeutics, Inc. announced that Marc Hedrick, M.D., President and Chief Executive Officer, will provide a comprehensive update of the Company’s recent activity and progress to date during a presentation at the 2023 Virtual June Investor Summit on Thursday, June 1, 2023, at 2:00 p.m. ET.

• Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

  6/1/2023

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) announced today that the U.S. Food and Drug Administration (“FDA”), after reviewing safety data on the program, has removed the partial clinical hold on patient enrollment for its MT-0169 trial.

• Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement

  6/1/2023

  Lexicon Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 23,924,705 shares of its common stock, par value $0.001.

• CoRegen Inc. Announces Publication of Preclinical Research Demonstrating Treatment with Modified Tregs Eliminates Tumors and Prevents Recurrence Without Side Effects

  6/1/2023

  CoRegen announced today the publication of research, titled, “Steroid receptor coactivator 3 is a key modulator of regulatory T cell-mediated tumor evasion,” in the peer-reviewed journal Proceedings of the National Academy of Sciences (PNAS).

• Spectros Medical Devices Pioneers Tissue Monitoring Technology

  6/1/2023

  Spectros Medical Devices has pioneered a groundbreaking technology for monitoring the health of transplanted tissues in post-cancer and trauma reconstruction surgery, specifically in the highly specialized field of reconstructive micro-surgery.